1
|
Fernández M, Semela D, Bruix J, Colle I,
Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol.
50:604–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Miura H, Miyazaki T, Kuroda M, Oka T,
Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y and Ohnishi
S: Increased expression of vascular endothelial growth factor in
human hepatocellular carcinoma. J Hepatol. 27:854–861. 1997.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Yamaguchi R, Yano H, Iemura A, Ogasawara
S, Haramaki M and Kojiro M: Expression of vascular endothelial
growth factor in human hepatocellular carcinoma. Hepatology.
28:68–77. 1998. View Article : Google Scholar : PubMed/NCBI
|
5
|
Terman BI, Carrion ME, Kovacs E, Rasmussen
BA, Eddy RL and Shows TB: Identification of a new endothelial cell
growth factor receptor tyrosine kinase. Oncogene. 6:1677–1683.
1991.PubMed/NCBI
|
6
|
Pajusola K, Aprelikova O, Korhonen J,
Kaipainen A, Pertovaara L, Alitalo R and Alitalo K: FLT4 receptor
tyrosine kinase contains seven immunoglobulin-like loops and is
expressed in multiple human tissues and cell lines. Cancer Res.
52:5738–5743. 1992.PubMed/NCBI
|
7
|
Shibuya M: Structure and dual function of
vascular endothelial growth factor receptor-1 (Flt-1). Int J
Biochem Cell Biol. 33:409–420. 2001. View Article : Google Scholar : PubMed/NCBI
|
8
|
Shibuya M and Claesson-Welsh L: Signal
transduction by VEGF receptors in regulation of angiogenesis and
lymphangiogenesis. Exp Cell Res. 312:549–560. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kendall RL, Wang G and Thomas KA:
Identification of a natural soluble form of the vascular
endothelial growth factor receptor, FLT-1, and its
heterodimerization with KDR. Biochem Biophys Res Commun.
226:324–328. 1996. View Article : Google Scholar : PubMed/NCBI
|
10
|
Koga J, Matoba T, Egashira K, Kubo M,
Miyagawa M, Iwata E, Sueishi K, Shibuya M and Sunagawa K: Soluble
Flt-1 gene transfer ameliorates neointima formation after wire
injury in flt-1 tyrosine kinase-deficient mice. Arterioscler Thromb
Vasc Biol. 29:458–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bagley RG, Kurtzberg L, Weber W, Nguyen
TH, Roth S, Krumbholz R, Yao M, Richards B, Zhang M, Pechan P, et
al: sFLT01: A novel fusion protein with antiangiogenic activity.
Mol Cancer Ther. 10:404–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Krishnan B, Torti FM, Gallagher PE and
Tallant EA: Angiotensin-(1–7) reduces proliferation and
angiogenesis of human prostate cancer xenografts with a decrease in
angiogenic factors and an increase in sFlt-1. Prostate. 73:60–70.
2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Owen LA, Uehara H, Cahoon J, Huang W,
Simonis J and Ambati BK: Morpholino-mediated increase in soluble
Flt-1 expression results in decreased ocular and tumor
neovascularization. PLoS One. 7:e335762012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Tipnis S, Viswanathan C and Majumdar AS:
Immunosuppressive properties of human umbilical cord-derived
mesenchymal stem cells: Role of B7-H1 and IDO. Immunol Cell Biol.
88:795–806. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Kidd S, Spaeth E, Dembinski JL, Dietrich
M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M and Marini FC:
Direct evidence of mesenchymal stem cell tropism for tumor and
wounding microenvironments using in vivo bioluminescent imaging.
Stem Cells. 27:2614–2623. 2009. View
Article : Google Scholar : PubMed/NCBI
|
16
|
Sasportas LS, Kasmieh R, Wakimoto H,
Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza
RL, Weissleder R and Shah K: Assessment of therapeutic efficacy and
fate of engineered human mesenchymal stem cells for cancer therapy.
Proc Natl Acad Sci USA. 106:4822–4827. 2009; View Article : Google Scholar : PubMed/NCBI
|
17
|
Loebinger MR, Kyrtatos PG, Turmaine M,
Price AN, Pankhurst Q, Lythgoe MF and Janes SM: Magnetic resonance
imaging of mesenchymal stem cells homing to pulmonary metastases
using biocompatible magnetic nanoparticles. Cancer Res.
69:8862–8867. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Ren C, Kumar S, Chanda D, Chen J, Mountz
JD and Ponnazhagan S: Therapeutic potential of mesenchymal stem
cells producing IFN-alpha in a mouse melanoma lung metastasis
model. Stem Cells. 26:2332–2338. 2008. View Article : Google Scholar : PubMed/NCBI
|
19
|
Nakamura K, Ito Y, Kawano Y, Kurozumi K,
Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y and Hamada H:
Antitumor effect of genetically engineered mesenchymal stem cells
in a rat glioma model. Gene Ther. 11:1155–1164. 2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Gao Y, Yao A, Zhang W, Lu S, Yu Y, Deng L,
Yin A, Xia Y, Sun B and Wang X: Human mesenchymal stem cells
overexpressing pigment epithelium-derived factor inhibit
hepatocellular carcinoma in nude mice. Oncogene. 29:2784–2794.
2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Li X, Lu Y, Huang W, Xu H, Chen X, Geng Q,
Fan H, Tan Y, Xue G and Jiang X: In vitro effect of
adenovirus-mediated human gamma interferon gene transfer into human
mesenchymal stem cells for chronic myelogenous leukemia. Hematol
Oncol. 24:151–158. 2006. View
Article : Google Scholar : PubMed/NCBI
|
22
|
Chen Q, Cheng P, Yin T, He H, Yang L, Wei
Y and Chen X: Therapeutic potential of bone marrow-derived
mesenchymal stem cells producing pigment epithelium-derived factor
in lung carcinoma. Int J Mol Med. 30:527–534. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zeng Y, Opeskin K, Goad J and Williams ED:
Tumor-induced activation of lymphatic endothelial cells via
vascular endothelial growth factor receptor-2 is critical for
prostate cancer lymphatic metastasis. Cancer Res. 66:9566–9575.
2006. View Article : Google Scholar : PubMed/NCBI
|
24
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
25
|
Kidd S, Spaeth E, Klopp A, Andreeff M,
Hall B and Marini FC: The (in) auspicious role of mesenchymal
stromal cells in cancer: Be it friend or foe. Cytotherapy.
10:657–667. 2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Kim SM, Oh JH, Park SA, Ryu CH, Lim JY,
Kim DS, Chang JW, Oh W and Jeun SS: Irradiation enhances the tumor
tropism and therapeutic potential of tumor necrosis factor-related
apoptosis-inducing ligand-secreting human umbilical cord
blood-derived mesenchymal stem cells in glioma therapy. Stem Cells.
28:2217–2228. 2010. View
Article : Google Scholar : PubMed/NCBI
|
27
|
Zou W, Zheng H, He TC, Chang J, Fu YX and
Fan W: LIGHT delivery to tumors by mesenchymal stem cells mobilizes
an effective antitumor immune response. Cancer Res. 72:2980–2989.
2012. View Article : Google Scholar : PubMed/NCBI
|
28
|
Ho IA, Toh HC, Ng WH, Teo YL, Guo CM, Hui
KM and Lam PY: Human bone marrow-derived mesenchymal stem cells
suppress human glioma growth through inhibition of angiogenesis.
Stem Cells. 31:146–155. 2013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Wels J, Kaplan RN, Rafii S and Lyden D:
Migratory neighbors and distant invaders: Tumor-associated niche
cells. Genes Dev. 22:559–574. 2008. View Article : Google Scholar : PubMed/NCBI
|
30
|
Studeny M, Marini FC, Dembinski JL,
Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE and Andreeff
M: Mesenchymal stem cells: Potential precursors for tumor stroma
and targeted-delivery vehicles for anticancer agents. J Natl Cancer
Inst. 96:1593–1603. 2004. View Article : Google Scholar : PubMed/NCBI
|
31
|
Son BR, Marquez-Curtis LA, Kucia M,
Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ and
Janowska-Wieczorek A: Migration of bone marrow and cord blood
mesenchymal stem cells in vitro is regulated by stromal-derived
factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves
matrix metalloproteinases. Stem Cells. 24:1254–1264. 2006.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Song C and Li G: CXCR4 and matrix
metalloproteinase-2 are involved in mesenchymal stromal cell homing
and engraftment to tumors. Cytotherapy. 13:549–561. 2011.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Klopp AH, Spaeth EL, Dembinski JL,
Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M and Marini FC:
Tumor irradiation increases the recruitment of circulating
mesenchymal stem cells into the tumor microenvironment. Cancer Res.
67:11687–11695. 2007. View Article : Google Scholar : PubMed/NCBI
|
34
|
Shibuya M: Vascular endothelial growth
factor and its receptor system: Physiological functions in
angiogenesis and pathological roles in various diseases. J Biochem.
153:13–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
35
|
Zeng Z, Huang WD, Gao Q, Su ML, Yang YF,
Liu ZC and Zhu BH: Arnebin-1 promotes angiogenesis by inducing
eNOS, VEGF and HIF-1α expression through the PI3K-dependent
pathway. Int J Mol Med. 36:685–697. 2015. View Article : Google Scholar : PubMed/NCBI
|
36
|
Kim SL, Lee ST, Trang KT, Kim SH, Kim IH,
Lee SO, Kim DG and Kim SW: Parthenolide exerts inhibitory effects
on angiogenesis through the downregulation of VEGF/VEGFRs in
colorectal cancer. Int J Mol Med. 33:1261–1267. 2014. View Article : Google Scholar : PubMed/NCBI
|
37
|
Takei Y, Mizukami H, Saga Y, Yoshimura I,
Hasumi Y, Takayama T, Kohno T, Matsushita T, Okada T, Kume A, et
al: Suppression of ovarian cancer by muscle-mediated expression of
soluble VEGFR-1/Flt-1 using adeno-associated virus serotype
1-derived vector. Int J Cancer. 120:278–284. 2007. View Article : Google Scholar : PubMed/NCBI
|
38
|
Justiniano SE, Elavazhagan S, Fatehchand
K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD,
et al: Fcγ receptor-induced soluble vascular endothelial growth
factor receptor-1 (VEGFR-1) production inhibits angiogenesis and
enhances efficacy of antitumor antibodies. J Biol Chem.
288:26800–26809. 2013. View Article : Google Scholar : PubMed/NCBI
|
39
|
Killion JJ, Radinsky R and Fidler IJ:
Orthotopic models are necessary to predict therapy of
transplantable tumors in mice. Cancer Metastasis Rev. 17:279–284.
1999. View Article : Google Scholar
|
40
|
Wang J, Xu L, Zeng W, Hu P, Zeng M, Rabkin
SD and Liu R: Treatment of human hepatocellular carcinoma by the
oncolytic herpes simplex virus G47delta. Cancer Cell Int.
14:832014. View Article : Google Scholar : PubMed/NCBI
|
41
|
Schmitz V, Raskopf E, Gonzalez-Carmona MA,
Vogt A, Rabe C, Leifeld L, Kornek M, Sauerbruch T and Caselmann W:
Plasminogen fragment K1-5 improves survival in a murine
hepatocellular carcinoma model. Gut. 56:271–278. 2007. View Article : Google Scholar : PubMed/NCBI
|
42
|
Zhu LM, Shi DM, Dai Q, Cheng XJ, Yao WY,
Sun PH, Ding Y, Qiao MM, Wu YL, Jiang SH and Tu SP: Tumor
suppressor XAF1 induces apoptosis, inhibits angiogenesis and
inhibits tumor growth in hepatocellular carcinoma. Oncotarget.
5:5403–5415. 2014. View Article : Google Scholar : PubMed/NCBI
|